On April 15, 2025 – KeYe Life  announced that its innovative small molecule drug KY2 has been officially accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), marking a critical milestone in its development and regulatory journey.

KY2 is an orally  small molecule drug targeting a key oncogenic pathway. Preclinical studies have demonstrated promising anti-tumor efficacy and a favorable safety profile across multiple cancer models. The acceptance by CDE reflects the authority’s recognition of KY2’s early-stage data and paves the way for subsequent clinical trials in China.

This represents a significant advancement in KeYe Life’s drug pipeline. It showcases KeYe Life’s scientific strength and persistent efforts in driving innovative oncology therapeutics.